Higher dose of blood thinner improves treatment of cancer-associated blood clots

June 3, 2014

Dr. Marc Carrier has published a study in the journal Thrombosis Research providing evidence that it is safe and effective to escalate the doses of blood thinners known as low molecular weight heparin (LMWH) in patients with cancer-associated blood clots, or thrombosis. This approach has long been suggested as a potential treatment option for patients who experience recurrent cancer-associated thrombosis, but had not been substantiated by a clinical study. Read the study.

About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease.

Media contact
Paddy Moore
Communications and Public Relations
Ottawa Hospital Research Institute
613-737-8899 x73687
613-323-5680 (cell)